|
|
cediranib An indole ether quinazoline derivative with antineoplastic activities. Competing with adenosine triphosphate, cediranib binds to and inhibits all three vascular endothelial growth factor receptor (VEGF-1,-2,-3) tyrosine kinases, thereby blocking VEGF-signaling, angiogenesis, and tumor cell growth. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
US brand name: | | Recentin | | | Foreign brand name: | | Recentin | | | Code name: | | AZD2171 | | |
|
|